British drug-cost watchdog recommends use of AbbVie's ovarian cancer therapy

NHS will now provide AbbVie’s targeted ovarian cancer drug Elahere to patients whose tumors no longer respond to chemotherapy, after NICE approved it under a confidential deal — it was previously available only in trials, privately, or compassionately.
The "guided missile" antibody‑drug conjugate is given every three weeks, has a more manageable side‑effect profile than chemo and extended survival in trials (about 17 vs 13 months).
The decision follows changes to NICE’s appraisal rules as part of a UK–US deal to widen access to medicines; initial funding comes from the Cancer Drugs Fund and a few hundred patients are expected to benefit in the first years.